Skip to main content

Table 1 Treatment duration, side effects, and sequelae of cCMV patients with GCV/VGCV

From: Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study

ID

CMV viral load (IU/mL)

Treatment duration

Reduction or suspension of therapy weeks after GCV/VGCV

Side effect

Sensorineural hearing loss

Neuro-development†

Before GCV/VGCV

6 weeks after GCV/VGCV

 

at birth

last visit

at 2 years

1

51,761

 < LoD*

6 weeks

None

None

None

None

No delay

2

64,649

 < LoD

6 months

Suspension (4 W, 6–11 W)

Elevated transaminases

Both ears

No change

Mild

3

88,674

 < LoD

6 months

None

None

Right ear

No change

No delay

4

150,000

 < LoD

6 weeks

None

None

None

None

Mild

5

87,688

5,099

3 months

None

None

None

None

No delay

6

10,994

7,535

4 months

Suspension (3 W, 9–11 W)

Reduction (4–8 W)

Neutropenia

None

None

Mild

7

116,600

31,975

6 months

Suspension (9–10, 12–17 W) reduction (4–8 W)

Neutropenia

None

None

Mild

8

271,309

280,000

3 months

None

None

None

None

Mild

9

18,445

1250

6 weeks

None

None

Both ears

No change

Mild

10

N.A§

2149

6 weeks

None

None

Both ears

No change

Mild

11

167,250

199,125

10 months

Suspension (2, 6–7, 29–32 W)

Neutropenia,

Elevated transaminases

Right ear

No change

Moderate

  1. CMV cytomegalovirus, GCV ganciclovir, VGCV valganciclovir; * < LoD (IU/): lower than limit of detection; §N.A. not available
  2. †Neurodevelopment level was defined according to the developmental quotient (DQ) as follows: no delay, > 75, mild 50–75, moderate